Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: An open, observational study

Seizure

Volumn 7, Issue 1, 1998, Pages 55-62

  Baulac, M ^a   Cavalcanti, D ^a   Semah, F ^a   Arzimanoglou, A ^a   Portal, J J ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Efficacy; Epilepsy; Gabapentin; Open label study; Partial seizures; Tolerability

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; VIGABATRIN;

ADULT; AGED; ARTICLE; ASTHENIA; ATAXIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOCAL EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SOMNOLENCE; TITRIMETRY; VERTIGO; WEIGHT GAIN;

EID: 0031935855     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(98)90009-7     Document Type: Article

References (19)

1. Leiderman, D.B. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled trials. Epilepsia 1994; 35 (Suppl. 5): S74-S76.
2. Crawford, P., Ghadiali, E., Lane, R., Blumhardt, L. and Chadwick, D. Gabapentin as an antiepileptic drug in man. Journal of Neurology, Neurosurgery and Psychiatry 1987; 50: 682-686.
3. Silvenius, J., Kälviäinen, R., Ylinin, A. and Riekkinen, P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991; 32: 539-542.
4. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990; 335: 1114-1117.
5. The US Gabapentin Study Group No 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo controlled, parallel-group study. Neurology 1993; 43: 2292-2298.
6. Anhut, H., Ashman, P., Feuerstein, T. J., et al. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia 1994; 35: 795-801.
7. Ojemann, L.M., Wilensky, A.J., Temkin, N.R., Chemlir, T., Ricker, B.A. and Wallace, J. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Research 1992; 13: 159-165.
8. The US Gabapentin Study Group. The long-term an efficacy of gabapentin (Neurontin®) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Research 1994; 18: 67-73.
9. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for classification of epilepsies and epileptic syndromes. Epilepsia 1985; 26: 268-278.
10. Brodie, M.J. Antiepileptic drugs, clinical trials, and the marketplace. Lancet 1996; 347: 777-778.
11. Goa, K.L. and Sorkin, E.M. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-427.
12. Chadwick, D.W. Gabapentin. Lancet 1994; 343: 89-91.
13. Dam, L., Gram, L. and Mumford, J.P. Design of clinical trials of new antiepileptic drugs. In: Antiepileptic Drugs (Eds R.H. Levy, R.H. Mattson and B.S. Meldrum). New York, Raven Press, 4th Edn, 1995: pp. 111-122.
14. Ferrendelli, J.A. Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy. Neurology 1995; 45: (Suppl. 2): S12-S16.
15. Dichter, M.A. and Brodie, M.J. New antiepileptic drugs. New England Journal of Medicine 1996; 334: 1583-1590.
16. Taylor, C.P. Gabapentin, mechanisms of action. In: Antiepileptic Drugs (Eds R.H. Levy, R.H. Mattson and B.S. Meldrum). New York, Raven Press, 4th Edn, 1995: pp. 829-841.
17. Petroff, O.A.C., Rothman, D.L., Behar, K.L., Lamoureux, D. and Mattson, R.H. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Annals of Neurology 1996; 39: 95-99.
18. Mattson, R.H., Petroff, O., Rothman, D. and Behar, K. Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. Epilepsia 1994; 35: (Suppl. 5): S29-S32.
19. Bruni, J. Neurontin as first add-on therapy in patients with partial seizures. Epilepsia 1996; 37 (Suppl. 5): 159.